Is there data supporting the extension of adjuvant olaparib beyond one year in patients with early-stage HER2-negative breast cancer and germline BRCA1/2 mutations?  

The current practice of the addition of 1 year of adjuvant olaparib in high-risk HER2-negative early breast cancer in those patients with germline pathogenic or likely pathogenic variants in BRCA1 or BRCA2 is based on the superior DFS and OS benefit reported in the Phase III OlympiA trial. Fortunate...

No.